manalikamdar

731 posts

manalikamdar

@mana1981

HematoOncologist, eternal optimist, passionate about making every moment count

Denver, CO Katılım Ekim 2009

434 Takip Edilen739 Takipçiler

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·9 Mar

Now published by Dr. @majorajay @CUHematology in @JNCI_Now: an original research article demonstrating earlier presentation and higher mortality of secondary colorectal cancers in childhood cancer survivors. #survivorship pubmed.ncbi.nlm.nih.gov/40838867/

CU Anschutz Lymphoma Program tweet media

English

410

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·9 Mar

Now published @ASTCT_Journal: Dr. @mana1981 contributed to an expert review on eligibility for CAR T-cell therapy, including for patients who do not meet clinical trial criteria. #tcellrx #lymsm pubmed.ncbi.nlm.nih.gov/41138816/

English

917

manalikamdar retweetledi

Kate Cwynarski@CwynKate·6 Mar

Glofitamab crosses the blood brain barrier and exhibits activity against primary and secondary CNS lymphoma ⁦@BloodAdvances⁩ American Society of Hematology ashpublications.org/bloodadvances/…

English

5.9K

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·17 Şub

Our @CULymphoma faculty Dr. @majorajay had a #Tandem26 abstract featured @OncLive for a study about bispecific antibodies after CAR-T in relapsed/refractory mantle cell lymphoma. @CUHematology is part of the nationwide CUBIC bispecific consortium. #lymsm onclive.com/view/real-worl…

English

163

manalikamdar retweetledi

Ajay Major, MD, MBA@majorajay·17 Şub

Many thanks to @OncLive for reviewing our #Tandem26 abstract on outcomes of CD20 bispecifics after CD19 CAR in R/R MCL, an analysis from the CUBIC Consortium. #lymsm #tcellrx Abstract link: astctjournal.org/article/S2666-… onclive.com/view/real-worl…

English

618

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·16 Şub

Our @CULymphoma lead Dr. @mana1981 was just published @TheLancet as part of the TRANSCEND FL trial of liso-cel in marginal zone lymphoma. #lymsm #tcellrx pubmed.ncbi.nlm.nih.gov/41692020/

English

535

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·14 Şub

Our newest @CULymphoma faculty Dr. @cduarte8490 presents aggressive lymphoma updates at @CUHematology 2026 Denver ASH Review. Dr. Duarte specializes in lymphoma with a focus on rare subtypes (PTLD, PCNSL). #lymsm

English

627

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·14 Şub

Packed house for our @CUHematology 2026 Denver ASH Review today! cc @CUAnschutz

Denver, CO 🇺🇸 English

439

manalikamdar retweetledi

Ajay Major, MD, MBA@majorajay·7 Şub

In Vail this weekend co-chairing the @TotalHealthConf 2026 Best of Hematology with Dr. Erin Schwab. I'll be tweeting slides from the conference, so follow along! #leusm #mmsm #lymsm

English

798

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·7 Şub

Dr. @StevenBairMD @CUHematology presents at @TotalHealthConf 2026 Best of Hematology in Vail about targetable pathways in CLL. #lymsm

English

168

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·3 Şub

Dr. @mana1981 @CULymphoma paper @ASTCT_Journal that nearly all post-CAR-T CRS & ICANS occurs in the first 2 weeks after infusion. This led to a reduced requirement for staying near the CAR-T center with a goal of better access to CAR-T. pubmed.ncbi.nlm.nih.gov/41235976/ #lymsm #tcellrx

English

382

manalikamdar@mana1981·24 Oca

An honor to be part of this special film celebrating CO’s 150th anniversary. Philanthropy at CU Anschutz doesn’t just support ideas,it accelerates discoveries and transforms patient care. Grateful to be included in this story and excited for what the next 150 years will bring

University of Colorado Anschutz@CUAnschutz

At #CUAnschutz, philanthropy makes it possible to change medicine and transform lives. Created by Colorado at 150 for the state’s 150th anniversary, this film celebrates the giving spirit that is shaping Colorado. 🎥

English

706

manalikamdar retweetledi

Loretta J. Nastoupil, MD@LNastoupilMD·17 Oca

Please join us on January 20 as we kick off our first Community Oncology Series with @@mana1981. The event is free and open to the public. Register athttps://soho.click/community-oncology-series @SocietyofHemOnc

English

842

manalikamdar retweetledi

Society of Hematologic Oncology (SOHO)@SocietyofHemOnc·7 Oca

Join us for our FREE talk & Q&A on expanding access to CAR-T therapy with @mana1981 for 4:30 to 5 pm CT on January 20 on Zoom with @LNastoupilMD Register for free at soho.click/community-onco…

Society of Hematologic Oncology (SOHO) tweet media

English

995

manalikamdar retweetledi

OncLive.com@OncLive·30 Ara

ICYMI 👀: @mana1981 of @CUAnschutz discusses the long-term efficacy findings from the phase 3 TRANSFORM trial of liso-cel in patients with relapsed/refractory LBCL.🩸 Watch now ▶️: onclive.com/view/dr-kamdar… @ASH_hematology #ASH25 #lymsm

English

603

manalikamdar retweetledi

VJHemOnc@VJHemOnc·20 Ara

Thank you to the wonderful Manali Kamdar (@mana1981) of @CUCancerCenter for speaking with us at #ASH25 to share insights from the long-term follow-up of the TRANSFORM trial comparing liso-cel to SoC for R/R LBCL. Watch the interview here: 👉 ow.ly/CO4q50XKgC2 👈 #LYMsm #CTSM #TrialUpdate #HemOnc #ImmunoOnc @ASH_hematology

English

622

manalikamdar retweetledi

Graham Collins@graham74GC·19 Ara

What is the risk of IgM MGUS to WM? Moreno et al: - 956 pts, Spain - 5y & 10y risk of WM: 13%, 20% - RFs: IgM ≥ 10g/L, B2M ≥ 3mg/L, BM infiltratn ≥ 20%, alb ≤ 40 g/L - In asymp pts, mortality similar to gen popn Useful data to guide management #lymsm onlinelibrary.wiley.com/doi/full/10.10…

English

5.3K

manalikamdar retweetledi

Society of Hematologic Oncology (SOHO)@SocietyofHemOnc·16 Ara

We are proud to announce the launch of Community Oncology Brown Bag Series, led by Dr. Loretta Nastoupil. This is free and open to the public and will be held monthly. Register at soho.click/community-onco… @mana1981 @jeffsharman @ninashah33 @MileHighMyeloma

English

1.8K

manalikamdar retweetledi

CancerNetwork®@CancerNetwrk·16 Ara

🎙️ This week's episode of ONCOLOGY On the Go is a compilation of some #ASH25 interviews! ⬇️ Find it on Spotify or click the link below ⬇️ hubs.li/Q03YddRJ0 #mmsm #lymsm #leusm | @MDAndersonNews | @mana1981 | @jenweiying

English

269

manalikamdar retweetledi

CU Anschutz Lymphoma Program@CULymphoma·16 Ara

Congratulations to our junior @CULymphoma faculty Dr. @majorajay on his first-author publication in @JNCI_Now: pubmed.ncbi.nlm.nih.gov/40838867/ #survivorship #onctwitter

CU Anschutz Cancer Center@CUCancerCenter

CU Cancer Center member Ajay Major (@majorajay), MD, MBA, led a study of more than 25,000 long-term childhood cancer survivors, to learn more about their rates of colorectal cancer and what their doctors can do about it ⬇️ bit.ly/3MkDl2t

English

2.2K

Keşfet

@majorajay @CUHematology @JNCI_Now @ASTCT_Journal @BloodAdvances @CULymphoma @OncLive @TheLancet